Literature DB >> 2895938

Further studies on the interaction between bromocriptine and SKF38393 in reserpine and alpha methyl-para-tyrosine-treated mice.

D M Jackson1, S B Ross, M Hashizume.   

Abstract

In a previous report, we showed that the relatively selective dopamine (DA) D-2 agonist bromocriptine (BRC), when combined with the selective D-1 agonist SKF38393, produced in DA-depleted mice a marked locomotor stimulation, despite BRC and SKF38393 being inactive by themselves (Jackson and Hashizume 1986). The present series of experiments was designed to further explore this interaction. In all experiments, mice were pretreated with reserpine and/or alpha methyl-p-tyrosine (AMPT). In mice pretreated with reserpine, AMPT or reserpine plus AMPT, BRC plus SKF38393 produced marked excitation whether the BRC was given 3 or 1 h prior to the SKF38393 challenge. However, while there was no absolute requirement that BRC be given a certain time before SKF38393, this factor was of some importance, with the onset of locomotor stimulation produced by the combination being much more rapid if the BRC was given 3 h rather than 1 h before the SKF38393. Interestingly, the degree of locomotor stimulation produced by the combination was always greatest in the animals premedicated with reserpine alone. If AMPT was also used (with or without reserpine), the stimulation produced by the combination was reduced, which may have resulted in part from a non-specific depressant effect of the AMPT. From these results, it seems as though endogenous DA is not required for BRC to work, provided that D-1 receptors are stimulated.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2895938     DOI: 10.1007/bf00174683

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  28 in total

1.  Effects of bromocriptine on adenylate cyclase and phosphodiesterase activities of rat striatum.

Authors:  G Pagnini; F Camanni; A Crispino; P Portaleone
Journal:  J Pharm Pharmacol       Date:  1978-02       Impact factor: 3.765

2.  The interactions of bromocriptine and lergotrile with dopamine and alpha-adrenergic receptors.

Authors:  J Y Lew; F Hata; T Ohashi; M Goldstein
Journal:  J Neural Transm       Date:  1977       Impact factor: 3.575

3.  Stereotyped behaviour in response to the selective D-2 dopamine receptor agonist RU 24213 is enhanced by pretreatment with the selective D-1 agonist SK&F 38393.

Authors:  M Mashurano; J L Waddington
Journal:  Neuropharmacology       Date:  1986-08       Impact factor: 5.250

Review 4.  Behavioural correlates of the action of selective D-1 dopamine receptor antagonists. Impact of SCH 23390 and SKF 83566, and functionally interactive D-1:D-2 receptor systems.

Authors:  J L Waddington
Journal:  Biochem Pharmacol       Date:  1986-11-01       Impact factor: 5.858

5.  Bromocriptine for levodopa-induced end-of-dose dystonia.

Authors:  M Hallett
Journal:  Lancet       Date:  1981-03-14       Impact factor: 79.321

6.  The antiparkinsonian efficacy of bromocriptine.

Authors:  A Lieberman; M Zolfaghari; D Boal; H Hassouri; B Vogel; A Battista; K Fuxe; M Goldstein
Journal:  Neurology       Date:  1976-05       Impact factor: 9.910

7.  Interaction of ergot drugs with central monoamine systems. Evidence for a high potential in the treatment of mental and neurological disorders.

Authors:  K Fuxe; B B Fredholm; L F Agnati; S O Ogren; B J Everitt; G Jonsson; J A Gustafsson
Journal:  Pharmacology       Date:  1978       Impact factor: 2.547

8.  Bromocriptine enhances the behavioural effects of apomorphine and dopamine after systemic or intracerebral injection in rats.

Authors:  O F Jenkins; D M Jackson
Journal:  Neuropharmacology       Date:  1986-11       Impact factor: 5.250

9.  Characterization of normal and supersensitive dopamine receptors: effects of ergot drugs and neuropeptides.

Authors:  K Fuxe; L F Agnati; C Köhler; D Kuonen; S O Ogren; K Andersson; T Hökfelt
Journal:  J Neural Transm       Date:  1981       Impact factor: 3.575

10.  Evidence for an irreversible interaction of bromocryptine with central dopamine receptors.

Authors:  M J Bannon; A A Grace; B S Bunney; R H Roth
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1980-05       Impact factor: 3.000

View more
  7 in total

1.  Locomotor-activating effects of the D2 agonist bromocriptine show environment-specific sensitization following repeated injections.

Authors:  D C Hoffman; R A Wise
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

Review 2.  The motor effects of bromocriptine--a review.

Authors:  D M Jackson; O F Jenkins; S B Ross
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

3.  Hypothalamic neuropeptide Y (NPY) and the attenuation of hyperphagia in streptozotocin diabetic rats treated with dopamine D1/D2 agonists.

Authors:  Dong-Yih Kuo
Journal:  Br J Pharmacol       Date:  2006-05-15       Impact factor: 8.739

4.  Enhancement by a single dose of reserpine (plus alpha methyl-p-tyrosine) of the central stimulatory effects evoked by dopamine D-1 and D-2 agonists in the mouse.

Authors:  S B Ross; D M Jackson; E M Wallis; S R Edwards
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-05       Impact factor: 3.000

5.  Dopamine deficiency contributes to early visual dysfunction in a rodent model of type 1 diabetes.

Authors:  Moe H Aung; Han Na Park; Moon K Han; Tracy S Obertone; Jane Abey; Fazila Aseem; Peter M Thule; P Michael Iuvone; Machelle T Pardue
Journal:  J Neurosci       Date:  2014-01-15       Impact factor: 6.167

6.  Circadian peak dopaminergic activity response at the biological clock pacemaker (suprachiasmatic nucleus) area mediates the metabolic responsiveness to a high-fat diet.

Authors:  S Luo; Y Zhang; M Ezrokhi; Y Li; T-H Tsai; A H Cincotta
Journal:  J Neuroendocrinol       Date:  2018-01       Impact factor: 3.627

7.  Dopamine receptor D1- and D2-agonists do not spark brown adipose tissue thermogenesis in mice.

Authors:  Francesca-Maria Raffaelli; Julia Resch; Rebecca Oelkrug; K Alexander Iwen; Jens Mittag
Journal:  Sci Rep       Date:  2020-11-19       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.